Featured News

Within the last year, at least three studies were conducted with the goal of determining the relationship between the amount of gluten ingested and the risk of developing celiac disease. An important review of these studies, conducted by Jonas Ludvigsson and CDF Research Committee Member Benjamin Lebwohl, concluded that new clinical trials must be conducted…

Researchers at the Beth Israel Deaconess Medical Center, including Celiac Disease Foundation Medical Advisory Board Member Dan Leffler, conducted a study to determine the effects of the gluten-free diet (GFD) on weight changes in celiac patients after diagnosis. The authors note that while weight gain would be welcome and expected in initially underweight patients, similar…

Scientist at Cincinnati Children’s Hospital awarded $1.5 million grant to study stem cells from patients with genetic diseases, including celiac disease, that impair one’s ability to properly absorb nutrients to help develop new therapies for malnutrition.

We put together a list of some of the most common perceived barriers to participating in clinical trials, and how to overcome them.

Cour Pharmaceuticals has announced a $420 million licensing deal with Takeda Pharmaceuticals following a favorable outcome of their phase 2 trial for celiac disease. The company released data from a small phase 2a study at the annual United European Gastroenterology organization meeting showing that its treatment, CNP-101, cut levels of inflammation-promoting cytokines. The technology was…

Parents using multiple kitchen appliances and utensils to prevent their child with celiac disease from being exposed to gluten may be able to eliminate some cumbersome steps. A new, preliminary study from Children’s National Hospital published in the journal Gastroenterology found no significant gluten transfer when tools like the same toaster or knives are used for both…

CEO Marilyn G. Geller’s testimony before the House Appropriations Subcommittee has helped secure report language in the House’s version of the 2020 Labor-HHS-Education bill demanding that the National Institute of Health (NIH) report to Congress in 90 days on its plans to aid celiac disease patients. This acknowledgment that celiac disease is a serious condition…

Researchers found that children with celiac disease have a 1.2-1.8 higher risk of psychological conditions such as depression, mood disorders, behavioral problems, ADHD, eating disorders, autism, and other intellectual disabilities.

CEO Marilyn G. Geller speaks at the 18th International Celiac Disease Symposium (ICDS).

ActoBio announces FDA has given permission to an Investigational New Drug (IND) application for Actobiotics® AG017, a therapeutic candidate for celiac disease.